Steven is a scientist and entrepreneur who is the CEO and founder of MitoDys Therapeutics and moonlights as a visiting researcher at Oxford University’s Structural Genomics Consortium. He is on the advisory board of the Rare Disease Initiative at Oxford University and is also currently a co-founder of Elpis Therapeutics limited and EpiCombi Therapeutics. He has a BSc (Hon) in Biochemistry from Simon Fraser University in Canada and an MSc. in Molecular and Developmental Biology from the University of Basel in Switzerland. He spent many years on Wall Street and in the City of London as a Financial Analyst, Investment Banker and Portfolio Manager at Robert Fleming, Donaldson Lufkin & Jenrette and Credit Suisse First Boston.